Keywords: Acetazolamide, Antiobesity Agent, Atypical Antipsychotic Agent, Carbonate Dehydratase, Carbonate Dehydratase Ii, Carbonate Dehydratase Inhibitor, Diclofenamide, Ethoxzolamide, Methazolamide, Placebo, Sulfonamide, Topiramate, Trifluoromethanesulfonamide, Unclassified Drug, Zonisamide, Adjuvant Therapy, Bipolar Disorder, Clinical Trial, Cytosol, Disorders Of Acid Base Balance, Drug Dose Increase, Drug Dose Reduction, Drug Mechanism, Drug Protein Binding, Drug Structure, Drug Synthesis, Drug Tolerability, Enzyme Activity, Enzyme Inhibition, Epilepsy, Glaucoma, Human, Lipogenesis, Low Calory Diet, Mitochondrion, Neurologic Disease, Nonhuman, Pathophysiology, Review, Schizophrenia, Side Effect, Structure Activity Relation, Unspecified Side Effect, Weight Gain, Weight Reduction, X Ray Crystallography, Anti-Obesity Agents, Carbonic Anhydrase Inhibitors, Fructose, Isoxazoles,
Affiliations: *** IBB - CNR ***
Istituto di Biostructure e Bioimmagini-CNR, via Mezzocannone 16, 80134 Naples, Italy
Università degli Studi di Firenze, Laboratorio di Chimica Bioinorganica, Rm. 188, Via della Lastruccia 3, I-50019 Sesto Fiorentino, Firenze, Italy
Universit degli Studi di Firenze, Laboratorio di Chimica Bioinorganica, Rm. 188, Via della Lastruccia 3, I-50019 Sesto Fiorentino, Firenze, Italy
References: Friedman, J.M., A war on obesity, not the obese (2003) Science, 299, pp. 856-85
Hill, J.O., Wyatt, H.R., Reed, G.W., Peters, J.C., Obesity and the environment: Where do we go from here? (2003) Science, 299, pp. 853-855
Ioannides-Demos, L.L., Proietto, J., Tonkin, A.M., McNeil, J.J., Safety of drug therapies used for weight loss and treatment of obesity (2006) Drug Saf, 29, pp. 277-302
Sidhaye, A., Cheskin, L.J., Pharmacologic treatment of obesity (2006) Adv. Psychosom. Med, 27, pp. 42-52
Davidson, M.H., Hauptman, J., Digirolamo, M., Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat (1999) JAMA, 281, pp. 235-242
Hollander, P.A., Elbein, S.C., Hirsch, I.B., Kelley, D., McGill, J., Taylor, T., Weiss, S.R., Hauptman, J., Role of orlistat in the treatment of obese patients with type 2 diabetes (1998) Diabetes Care, 21, pp. 1288-1294
Mcnelly, W., Goa, A.L., Sibutramine in obesity: A review (1998) Drugs, 56, pp. 1093-1124
Group, T.S.C.S. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes. Metab., 2000, 2, 175-187Bays, H.E., Current and investigational antiobesity agents and obesity therapeutic treatment targets (2004) Obes. Res, 12, pp. 1197-1211
Gadde, K.M., Endocannabinoid receptor antagonists and other emerging pharmacological strategies for weight reduction (2005) Curr. Drug Targets Cardiovasc. Haematol. Disord, 5, pp. 549-556
Pi-Sunyer, F.X., Aronne, L.J., Heshmati, H.M., Devin, J., Rosenstock, J., RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight orAobese patients: RIO-North America: a randomized controlled trial (2006) JAMA, 295, pp. 761-775
Supuran, C.T., Scozzafava, A., Casini, A., Carbonic anhydrase inhibitors (2003) Med. Res. Rev, 23, pp. 146-189
Supuran, C.T., Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesit (2003) Expert Opin. Ther. Pat, 13, pp. 1545-1550
(2004) Carbonic anhydrase - Its inhibitors and activators, pp. 1-363. , Supuran, C.T, Scozzafava, A, Conway, J, Eds, CRC Press, Boca Raton FL, USA, and references cited therein
Dodgson, S.J., Inhibition of mitochondrial carbonic anhydrase: A discrepancy examined (1987) J. Appl. Physiol, 63, pp. 2134-2141
Dodgson, S.J., Cherian, K., Mitochondrial carbonic anhydrase is involved in rat renal glucose synthesis (1989) Am. J. Physiol, 257, pp. E791-E796
Spencer, I.M., Hargreaves, I., Chegwidden, W.R., Effect of the carbonic anhydrase inhibitor acetazolamide on lipid synthesis in the locust (1988) Biochem. Soc. Trans, 16, pp. 973-974
Chegwidden, W.R., Spencer, I.M., Carbonic anhydrase provides bicarbonate for de novo lipogenesis in the locus (1996) Comp. Biochem. Physiol, 115 B, pp. 247-254
Chegwidden, W.R., Dodgson, S.J., Spencer, I.M., The roles of carbonic anhydrase in metabolism, cell growth and cancer in animals (2000) The Carbonic Anhydrases - New Horizons, pp. 343-363. , Chegwidden W.R, Edwards, Y, Carter, N. Eds, Birkhäuser Verlag, Basel
Lynch, C.J., Fox, H., Hazen, S.A., Stanley, B.A., Dodgson, S.J., Lanoue, K.F., Role of hepatic carbonic anhydrase in de novo lipogenesis (1995) Biochem. J, 310, pp. 197-202
Hazen, S.A., Waheed, A., Sly, W.S., Lanoue, K.F., Lynch, C.J., Differentiation-dependent expression of CA V and the role of carbonic anhydrase isozymes in pyruvate carboxylation in adipocytes (1996) FASEB J, 10, pp. 481-490
Atwood, P.V., The structure and mechanism of action of pyruvate carboxylase (1995) Int. J. Biochem. Cell Biol, 27, pp. 231-249
Alldred, J.B., Reilly, K.E., Short-term regulation of acetyl CoA carboxylase in tissues of higher animals (1997) Prog. Lipid Res, 35, pp. 371-385
Forster, R.E., Dodgson, S.J., Membrane transport and provision of substrates for carbonic anhydrase in vertebrates (2000) The Carbonic Anhydrases - New Horizons, pp. 263-280. , Chegwidden W.R, Edwards, Y, Carter, N. Eds, Birkhäuser Verlag, Basel
Parkkila, S., An overview of the distribution and function of carbonic anhydrase isozymes in mammals (2000) The Carbonic Anhydrases - New Horizons, pp. 79-94. , Chegwidden W.R, Edwards, Y, Carter, N. Eds, Birkhäuser Verlag, Basel
Parkkila, S., Parkkila, A.K., Kivelä, J., Role of carbonic anhydrase and its inhibitors in biological science related to gastroenterology, neurology and nephrology (2004) Carbonic anhydrase, its inhibitors and activators, pp. 283-301. , Supuran, C.T, Scozzafava, A, Conway, J. Eds, CRC Press, Boca Raton
Scozzafava, A., Menabuoni, L., Mincione, F., Briganti, F., Mincione, G., Supuran, C.T., Carbonic anhydrase inhibitors: Perfluoroalkyl/ aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure lowering agents with prolonged duration of action (2000) J. Med. Chem, 43, pp. 4542-4551
Supuran, C.T., Briganti, F., Scozzafava, A., Sulfenamidosulfonamides as inhibitors of carbonic anhydrase isozymes I, II and IV (1997) J. Enzyme Inhib, 12, pp. 175-190
Ilies, M., Supuran, C.T., Scozzafava, A., Casini, A., Mincione, F., Menabuoni, L., Caproiu, M.T., Banciu, M.D., Carbonic anhydrase inhibitors. Sulfonamides incorporating furan-,thiophene- and pyrrole-carboxamido groups possess strong topical intraocular pressure lowering properties as aqueous suspensions (2000) Bioorg. Med. Chem, 8, pp. 2145-2155
Ilies, M.A., Vullo, D., Pastorek, J., Scozzafava, A., Ilies, M., Caproiu, M.T., Pastorekova, S., Supuran, C.T., Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX with halogenosulfanilamide and halogeno-aminophenylbenzolamide derivatives (2003) J. Med. Chem, 46, pp. 2187-2196
Scozzafava, A., Briganti, F., Mincione, G., Menabuoni, L., Mincione, F., Supuran, C.T., Carbonic anhydrase inhibitors: Synthesis of water-soluble, amino acyl/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route (1999) J. Med. Chem, 42, pp. 3690-3700
Winum, J.-Y., Vullo, D., Casini, A., Montero, J.-L., Scozzafava, A., Supuran, C.T., Carbonic anhydrase inhibitors: Inhibition of cytosolic isozymes I and II and the transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors (2003) J. Med. Chem, 46, pp. 2197-2204
Edmonds, H.L., Jiang, Y.D., Zhang, P.Y., Shank, R.P., Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy (1996) Life Sci, 59, pp. 127-131
Stringer, J.L., A comparison of topiramate and acetazolamide on seizure duration and paired-pulse inhibition in the dentate gyrus of the rat (2000) Epilepsy Res, 40, pp. 147-153
Sabers, A., Gram, L., Newer anticonvulsants: Comparative review of drug interactions and adverse effects (2000) Drugs, 60, pp. 23-33
Bourgeois, B.F.D., Pharmacokinetics and pharmacodynamics of topiramate (2000) J. Child. Neurol, 15, pp. S27-S30
Perucca, E. Progress report on new antiepileptic drugs: Summary of the Fifth Eilat Conference. Epilepsy Res., 2001, 43, 11-18Gordon, A., Price, L.H., Mood stabilization and weight loss with topiramate (1999) Am. J. Psychiatry, 156, pp. 968-969
Picard, F., Deshaies, Y., Lalonde, J., Samson, P., Richard, D., Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats (2000) Obesity Res, 8, pp. 656-663
Casini, A., Antel, J., Abbate, F., Scozzafava, A., David, S., Waldeck, H., Schäfer, S., Supuran, C.T., Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/ sulfamides with isozymes I, II and IV (2003) Bioorg. Med. Chem. Lett, 13, pp. 841-845
Vullo, D., Franchi, M., Gallori, E., Antel, J., Scozzafava, A., Supuran, C.T., Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides (2004) J. Med. Chem, 47, pp. 1272-1279
Nishimori, I., Vullo, D., Innocenti, A., Scozzafava, A., Mastrolorenzo, A., Supuran, C.T., Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors (2005) J. Med. Chem, 48, pp. 7860-7866
Lynch, C.J. Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity, 2006, 14, 36-51 . 48 Lin, Y.H.
Hsiao, M.C. Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate. Psychiatry. Clin. Neurosci., 2005, 59, 613-615Zareba, G., Zonisamide: Review of its use in epilepsy therapy (2005) Drug Today (Barc.), 41, pp. 589-597
Canitano, R., Clinical experience with Topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders (2005) Brain Dev, 27, pp. 228-232
De Simone, G., Di Fiore, A., Menchise, V., Pedone, C., Antel, J., Casini, A., Scozzafava, A., Supuran, C.T., Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: Solution and X-ray crystallographic studies (2005) Bioorg. Med. Chem. Lett, 15, pp. 2315-2320
Kim, C.S., Zonisamide effective for weight loss in women (2003) J. Fam. Pract, 52, pp. 600-601
Gadde, K.M., Franciscy, D.M., Wagner 2nd, H.R., Krishnan, K.R., Zonisamide for weight loss in obese adults: A randomized controlled trial (2003) JAMA, 289, pp. 1820-1825
Friedman, J. M., A war on obesity, not the obese (2003) Science, 299, pp. 856-85
Hill, J. O., Wyatt, H. R., Reed, G. W., Peters, J. C., Obesity and the environment: Where do we go from here? (2003) Science, 299, pp. 853-855
Davidson, M. H., Hauptman, J., Digirolamo, M., Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat (1999) JAMA, 281, pp. 235-242
Hollander, P. A., Elbein, S. C., Hirsch, I. B., Kelley, D., McGill, J., Taylor, T., Weiss, S. R., Hauptman, J., Role of orlistat in the treatment of obese patients with type 2 diabetes (1998) Diabetes Care, 21, pp. 1288-1294
Group, T. S. C. S. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes. Metab., 2000, 2, 175-187Bays, H. E., Current and investigational antiobesity agents and obesity therapeutic treatment targets (2004) Obes. Res, 12, pp. 1197-1211
Gadde, K. M., Endocannabinoid receptor antagonists and other emerging pharmacological strategies for weight reduction (2005) Curr. Drug Targets Cardiovasc. Haematol. Disord, 5, pp. 549-556
Pi-Sunyer, F. X., Aronne, L. J., Heshmati, H. M., Devin, J., Rosenstock, J., RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight orAobese patients: RIO-North America: a randomized controlled trial (2006) JAMA, 295, pp. 761-775
Supuran, C. T., Scozzafava, A., Casini, A., Carbonic anhydrase inhibitors (2003) Med. Res. Rev, 23, pp. 146-189
Supuran, C. T., Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesit (2003) Expert Opin. Ther. Pat, 13, pp. 1545-1550
Dodgson, S. J., Inhibition of mitochondrial carbonic anhydrase: A discrepancy examined (1987) J. Appl. Physiol, 63, pp. 2134-2141
Dodgson, S. J., Cherian, K., Mitochondrial carbonic anhydrase is involved in rat renal glucose synthesis (1989) Am. J. Physiol, 257, pp. E791-E796
Spencer, I. M., Hargreaves, I., Chegwidden, W. R., Effect of the carbonic anhydrase inhibitor acetazolamide on lipid synthesis in the locust (1988) Biochem. Soc. Trans, 16, pp. 973-974
Chegwidden, W. R., Spencer, I. M., Carbonic anhydrase provides bicarbonate for de novo lipogenesis in the locus (1996) Comp. Biochem. Physiol, 115 B, pp. 247-254
Lynch, C. J., Fox, H., Hazen, S. A., Stanley, B. A., Dodgson, S. J., Lanoue, K. F., Role of hepatic carbonic anhydrase in de novo lipogenesis (1995) Biochem. J, 310, pp. 197-202
Hazen, S. A., Waheed, A., Sly, W. S., Lanoue, K. F., Lynch, C. J., Differentiation-dependent expression of CA V and the role of carbonic anhydrase isozymes in pyruvate carboxylation in adipocytes (1996) FASEB J, 10, pp. 481-490
Atwood, P. V., The structure and mechanism of action of pyruvate carboxylase (1995) Int. J. Biochem. Cell Biol, 27, pp. 231-249
Alldred, J. B., Reilly, K. E., Short-term regulation of acetyl CoA carboxylase in tissues of higher animals (1997) Prog. Lipid Res, 35, pp. 371-385
Forster, R. E., Dodgson, S. J., Membrane transport and provision of substrates for carbonic anhydrase in vertebrates (2000) The Carbonic Anhydrases - New Horizons, pp. 263-280. , Chegwidden W. R, Edwards, Y, Carter, N. Eds, Birkh user Verlag, Basel
Supuran, C. T., Briganti, F., Scozzafava, A., Sulfenamidosulfonamides as inhibitors of carbonic anhydrase isozymes I, II and IV (1997) J. Enzyme Inhib, 12, pp. 175-190
Ilies, M. A., Vullo, D., Pastorek, J., Scozzafava, A., Ilies, M., Caproiu, M. T., Pastorekova, S., Supuran, C. T., Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX with halogenosulfanilamide and halogeno-aminophenylbenzolamide derivatives (2003) J. Med. Chem, 46, pp. 2187-2196
Winum, J. -Y., Vullo, D., Casini, A., Montero, J. -L., Scozzafava, A., Supuran, C. T., Carbonic anhydrase inhibitors: Inhibition of cytosolic isozymes I and II and the transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors (2003) J. Med. Chem, 46, pp. 2197-2204
Shank, R. P., Gardocki, J. F., Vaught, J. L., Davis, C. B., Schupsky, J. J., Raffa, R. B., Dodgson, S. J., Marianoff, B. E., Topiramate: Preclinical evaluation of structurally novel anticonvulsant (1994) Epilepsia, 35, pp. 450-460
Edmonds, H. L., Jiang, Y. D., Zhang, P. Y., Shank, R. P., Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy (1996) Life Sci, 59, pp. 127-131
Stringer, J. L., A comparison of topiramate and acetazolamide on seizure duration and paired-pulse inhibition in the dentate gyrus of the rat (2000) Epilepsy Res, 40, pp. 147-153
Bourgeois, B. F. D., Pharmacokinetics and pharmacodynamics of topiramate (2000) J. Child. Neurol, 15, pp. S27-S30
Lynch, C. J. Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity, 2006, 14, 36-51. 48 Lin, Y. H.
Hsiao, M. C. Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate. Psychiatry. Clin. Neurosci., 2005, 59, 613-615Zareba, G., Zonisamide: Review of its use in epilepsy therapy (2005) Drug Today (Barc.), 41, pp. 589-597
Kim, C. S., Zonisamide effective for weight loss in women (2003) J. Fam. Pract, 52, pp. 600-601
Gadde, K. M., Franciscy, D. M., Wagner 2nd, H. R., Krishnan, K. R., Zonisamide for weight loss in obese adults: A randomized controlled trial (2003) JAMA, 289, pp. 1820-1825